Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

Syndax Pharmaceuticals (SNDX) has seen a 45.4% gain over the past four weeks, closing at $13.45, with Wall Street analysts projecting a mean price target of $34.75, indicating a 158.4% upside. While the article cautions against relying solely on price targets due to their inherent variability and potential for bias, it highlights that the strong agreement among analysts in upwardly revising SNDX's EPS estimates—evidenced by an 11.9% increase in the Zacks Consensus Estimate over the past month—provides a more credible signal for potential near-term upside, further supported by a Zacks Rank #2 (Buy).

Analysis

Syndax Pharmaceuticals (SNDX) has demonstrated significant positive momentum, closing at $13.45 after a 45.4% gain over the last four weeks. While Wall Street's mean price target of $34.75 suggests a remarkable 158.4% potential upside, this forecast is accompanied by a high degree of uncertainty, evidenced by a wide standard deviation of $12.74 across the 12 analyst estimates. The article posits that a more reliable indicator of near-term performance is the trend in earnings estimate revisions. For SNDX, the Zacks Consensus Estimate for the current year has increased by 11.9% in the past month, a move supported by five upward revisions and no downward revisions. This unanimous positive revision trend, combined with a Zacks Rank #2 (Buy), provides a stronger, empirically-backed signal of improving earnings prospects and potential stock appreciation than the speculative price targets alone.

Key Decisions for Investors

• Investors should prioritize the positive trend in earnings estimate revisions, where the 11.9% increase in the consensus estimate provides a more tangible bullish signal than the highly speculative mean price target.
• The high standard deviation of $12.74 in price targets signals significant analyst disagreement and implies a high level of potential stock volatility, which should be factored into risk management and position sizing.
• Given the strong upward revisions in earnings expectations, investors could view the stock's fundamental outlook as improving, warranting further due diligence on the specific drivers behind this analyst optimism.